PTG

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

Retrieved on: 
Monday, March 11, 2024

PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.
  • Its manufacturing facility is one of Europe’s largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines.
  • PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies from future partners.
  • “This certification is an important recognition of PolTREG’s leading capabilities in manufacturing cellular therapies, a highly sophisticated process that requires deep experience to master,” said Prof. Piotr Trzonkowski, Chief Executive Officer of PolTREG.

PolTREG appoints Dan Shelly as Chief Business Development Officer

Retrieved on: 
Wednesday, February 21, 2024

“I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.

Key Points: 
  • “I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.
  • Dr Shelly is an astute veteran of the life science industry, with a deep understanding of biology and the Treg cell therapies that PolTREG is developing.
  • He was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland.

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

Retrieved on: 
Tuesday, January 30, 2024

PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland, where the company is completing its own state-of-the-art manufacturing facilities.
  • When found in the body, Treg cells are polyclonal, meaning they can react to a number of different antigenic triggers.
  • PolTREG (Gdańsk, Poland; WSA:PTG) is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs).

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

Retrieved on: 
Tuesday, January 16, 2024

The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.

Key Points: 
  • The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.
  • Many of PolTREG’s patent submissions are primary in the field, given that its team performed the first-in-human trials with Treg cell therapies in graft-versus-host disease in 2007-2009.
  • Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready to start Phase 2/3 clinical testing, upon partnership.
  • PolTREG also is developing engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, all of which are in the preclinical stage.

Hudson Hill Capital Announces Investment in MarketTime

Retrieved on: 
Tuesday, December 5, 2023

NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hudson Hill Capital ("HHC"), a private investment firm founded by Eric Rosen, today announced a significant majority investment in MarketTime, a SaaS platform that offers a comprehensive set of features to facilitate wholesale retail commerce between brands, manufacturer representatives, agents and retailers.

Key Points: 
  • NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hudson Hill Capital ("HHC"), a private investment firm founded by Eric Rosen, today announced a significant majority investment in MarketTime , a SaaS platform that offers a comprehensive set of features to facilitate wholesale retail commerce between brands, manufacturer representatives, agents and retailers.
  • Chris Happ, Chief Executive Officer of MarketTime, commented, "The MarketTime platform facilitates over $6 billion of wholesale retail commerce.
  • Eric Rosen, Managing Partner of Hudson Hill, said, "This transaction fits well with the HHC approach to investing, helping founder-led businesses inflect their growth through the targeted application of the HHC playbook.
  • Winston & Strawn LLP acted as legal advisor to Hudson Hill.

Blue Apron Holdings, Inc. Reports Second Quarter 2023 Results

Retrieved on: 
Wednesday, August 9, 2023

All periods presented have been adjusted to reflect the Company’s one-for-twelve reverse stock split that became effective on June 7, 2023.

Key Points: 
  • All periods presented have been adjusted to reflect the Company’s one-for-twelve reverse stock split that became effective on June 7, 2023.
  • The Company incurred approximately $0.4 million in the second quarter of 2023 and expects to incur the remainder of such expenses during the third quarter of 2023.
  • By year-end 2024, Blue Apron expects to be adjusted EBITDA profitable and to achieve year-over-year revenue growth.
  • A recording of the webcast will be available on Blue Apron’s Investor Relations website at investors.blueapron.com following the conference call.

Blue Apron Shares Business Update Following Its Recent Shift to an Asset-Light Model

Retrieved on: 
Tuesday, June 27, 2023

Today, Blue Apron (NYSE: APRN) shared a business update following the previously announced closing of the transaction with FreshRealm on June 9, 2023.

Key Points: 
  • Today, Blue Apron (NYSE: APRN) shared a business update following the previously announced closing of the transaction with FreshRealm on June 9, 2023.
  • We believe that moving to an asset-light model via the FreshRealm transaction was the right next step to help us execute this strategy.
  • We will continue to manage PTG&A in the retained Blue Apron business through additional headcount and other cost reductions in connection with the shift to the asset-light model, and expect to implement these cost reductions over the coming months.
  • A recording of the webcast will be available on Blue Apron’s Investor Relations website at investors.blueapron.com following the conference call.

PTSD Advice for Veterans: How to Grow After Trauma

Retrieved on: 
Wednesday, June 21, 2023

JACKSONVILLE, Fla., June 21, 2023 /PRNewswire/ -- What does life look like with post-traumatic stress disorder (PTSD)? For Tonya Oxendine, who served three decades in the U.S. Army, life with PTSD is full of laughter and joy. That was not always the case.

Key Points: 
  • JACKSONVILLE, Fla., June 21, 2023 /PRNewswire/ -- What does life look like with post-traumatic stress disorder (PTSD)?
  • For Tonya Oxendine, who served three decades in the U.S. Army, life with PTSD is full of laughter and joy.
  • This year, veterans from WWP programs and partners were invited to share advice for their peers with PTSD who may be hesitant to accept the help they deserve.
  • WWP programs and partnerships leverage these approaches and more to ensure warriors with PTSD can achieve their highest ambitions.

Boulder Crest Foundation Declares June 13 National Posttraumatic Growth Day

Retrieved on: 
Tuesday, June 13, 2023

BLUEMONT, Va., June 13, 2023 /PRNewswire-PRWeb/ -- More than 20 percent of Americans struggle with their mental health, and far too many of them feel as though they are destined to live diminished lives. It's time to change the conversation, and move beyond labels and diagnoses like PTSD, Depression, and Anxiety, so we can enable people to turn their struggle into strength and Posttraumatic Growth (PTG). To make that possible, Boulder Crest Foundation, the "home of Posttraumatic Growth," is pleased to announce that as of 2023, June 13 will annually mark National Posttraumatic Growth Day.

Key Points: 
  • To make that possible, Boulder Crest Foundation , the "home of Posttraumatic Growth," is pleased to announce that as of 2023, June 13 will annually mark National Posttraumatic Growth Day.
  • We can and must do better to spread the word about Posttraumatic Growth, and the establishment of National Posttraumatic Growth Day is a great start."
  • National Posttraumatic Growth Day acknowledges that what doesn't kill us, makes us stronger and wiser.
  • "The establishment of National Posttraumatic Growth Day is an important part of starting to change the conversation around trauma," said Dr. Richard Tedeschi, Executive Director, Boulder Crest Institute, and co-founder of the science of PTG.

Blue Apron Announces Closing of Transaction with FreshRealm to Execute Its Asset-Light Model and Focus on Its Direct-to-Consumer Business

Retrieved on: 
Friday, June 9, 2023

Under the definitive agreements entered into today, Blue Apron transferred its operational infrastructure to FreshRealm, including fulfillment centers, equipment, know-how and related personnel.

Key Points: 
  • Under the definitive agreements entered into today, Blue Apron transferred its operational infrastructure to FreshRealm, including fulfillment centers, equipment, know-how and related personnel.
  • Blue Apron is now an asset-light company, focused on the growth of its direct-to-consumer business.
  • In addition, Blue Apron expects to accelerate the expansion of its product offerings, including the addition of new convenient options.
  • In addition, Blue Apron and FreshRealm entered into license agreements, under which Blue Apron licensed to FreshRealm certain rights regarding the ability to use the Blue Apron brand in certain retail channels and the right to use certain Blue Apron software.